Showing results (1-10 of 352) with videos related to
Sort By:
Pageof 36
Drugs & Aging|July 1, 2026
Targeted Treatment for Hyperuricemia: The Drug PipelineAustin Barry, Lindsay N Helget, Ted R MikulsRheumatic Diseases Clinics of North America|November 4, 2022
Environmental Triggers of Hyperuricemia and GoutLindsay N Helget, Ted R MikulsCurrent Opinion in Rheumatology|December 22, 2023
Health disparities in goutLindsay N Helget, Ted R MikulsArthritis Care & Research|June 1, 2020
Incidence, Prevalence, and Burden of Gout in the Veterans Health AdministrationLindsay N Helget, Bryant R England, Punyasha Roul, et al.Arthritis Care & Research|August 4, 2025
Chronic Opioids in Gout: A Matched Cohort Study from the Veteran's Health AdministrationLindsay N Helget, Bryant R England, Punyasha Roul, et al.Arthritis Care & Research|March 16, 2022
Cause-Specific Mortality in Patients With Gout in the US Veterans Health Administration: A Matched Cohort StudyLindsay N Helget, Bryant R England, Punyasha Roul, et al.Arthritis & Rheumatology (Hoboken, N.J.)|August 17, 2022
Associations Between Low Serum Urate, Body Composition, and MortalityJoshua F Baker, David R Weber, Tuhina Neogi, et al.Best Practice & Research. Clinical Rheumatology|August 14, 2003
Co-morbidity in rheumatoid arthritisTed R MikulsArthritis Care & Research|August 7, 2025
Improvements in Health-Related Quality of Life with Treat-to-Target Urate-Lowering Therapy in Gout: A Post-hoc Analysis of a Randomized Multicenter TrialAustin Barry, Bryant R England, Harlan Sayles, et al.Arthritis & Rheumatology (Hoboken, N.J.)|June 26, 2024
Comparison of Gout Flares With the Initiation of Treat-to-Target Allopurinol and Febuxostat: A Post-Hoc Analysis of a Randomized Multicenter TrialAustin Barry, Lindsay N Helget, Maria Androsenko, et al.Pageof 36